Beamtree Holdings Limited (ASX: $BMT) has released its trading and operational update for the three months ending 31 March 2024 (Q3 FY24) and for the 9 months to 31 March 2024. The company reported a +20% year-on-year growth in Annual Recurring Revenue (ARR) at the end of Q3 FY24, with international revenue growth of 47% year to date. Operating profit for Q3 FY24 was $0.1m, a significant improvement from the $0.5m operating loss in Q3 FY23. Cash at 31 March 2024 stood at $4.3m, reflecting a positive trend compared to the previous year. Beamtree remains focused on closing significant contracts before the end of FY24 to expand in its core international markets, the UK, Canada, and Saudi Arabia.
The Company's strategic partnerships with Lean in Saudi Arabia and Abbott Laboratories Inc continue to provide significant opportunities and contribute to the strong FY25 and FY26 pipeline. We are pleased with the progress made in Q3 FY24, especially the positive operating profit and the international expansion. Our focus on delivering innovative solutions in the healthcare sector has been well-received, as evidenced by the significant contract wins and the promising sales pipeline. We remain committed to our strategy of expanding in key international markets and leveraging our partnerships to drive future growth.
Beamtree's Q3 FY24 trading update reflects a robust performance with notable achievements in revenue growth, international expansion, and the delivery of a positive operating profit. The company's focus on expanding in core international markets, strategic partnerships, and the strong pipeline for FY25 and FY26 positions it for continued growth. With a solid financial position and ongoing investment in products and capabilities, Beamtree is well-positioned to capitalize on opportunities in the healthcare sector. The outlook remains positive as the company aims to secure significant contracts before the end of FY24 and continue its expansion in the UK, Canada, and Saudi Arabia, aligning with its long-term corporate strategy.